Bioxel Pharma Inc.
TSX VENTURE : BIP

Bioxel Pharma Inc.

May 25, 2006 07:30 ET

REMINDER/Bioxel Pharma Inc.: Annual General Meeting of Shareholders

MONTREAL, QUEBEC--(CCNMatthews - May 25, 2006) - The management of Bioxel Pharma Inc. (TSX VENTURE:BIP) cordially invites you to attend the Annual General Meeting of Shareholders to be held on:



Thursday, May 25, 2006 at 1:30 p.m.
Chateau Bonne Entente
Salle G. Dube
3400 Chemin Sainte-Foy
Sainte-Foy, Quebec


In 2005 and early 2006, Bioxel Pharma multiplied its initiatives and agreements to increase and balance its market presence in North America and Europe, to expand its product mix in order to accelerate profitable revenue growth, and to increase the productivity of its manufacturing chain. At the Annual Meeting, Pascal Delmas, President and Chief Executive Officer, and Andre Boulet, Chairman of the Board, will specifically present the strategies Bioxel will implement to achieve its business and financial objectives. Results for the first quarter of the current fiscal year will also be disclosed.

A press briefing will be held right after the Meeting for members of the media.

For those unable to attend the event, the Meeting will be broadcast (audio and PowerPoint) at 1:30 p.m. on Thursday, May 25, 2006 on www.bioxelpharma.com, and will subsequently be available on this website.

Bioxel Pharma Inc. is an emerging leader in biopharmaceuticals, focused on developing, manufacturing and marketing taxane pharmaceutical ingredients. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis, Alzheimer's disease and cardiovascular disease. The Corporation sells cGMP paclitaxel and develops a portfolio of other generic taxane APIs and taxane-based proprietary products for improved cancer therapy.

The common shares of Bioxel Pharma are traded on the TSX Venture Exchange under the ticker symbol BIP.

Contact Information

  • CG3 Inc.
    Daniel Rheault
    Suzanne Roy
    (514) 286-5600